You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Litigation Details for Finjan, Inc. v. Blue Coat Systems, Inc. (N.D. Cal. 2015)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Finjan, Inc. v. Blue Coat Systems, Inc.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis: Finjan, Inc. v. Blue Coat Systems, Inc. | 5:15-cv-03295

Last updated: February 2, 2026

Executive Summary

This case involves patent infringement allegations filed by Finjan, Inc. against Blue Coat Systems, Inc. before the United States District Court for the Northern District of California. Finjan accused Blue Coat of infringing multiple patents related to cybersecurity technologies. The litigation has spanned several years, marked by procedural motions, claim constructions, and a trial verdict, culminating in a substantial damages award for Finjan. The case underscores ongoing patent enforcement efforts within cybersecurity, highlighting legal strategies, patent scope disputes, and post-trial developments.

Case Background

Parties

Plaintiff Finjan, Inc.
Defendant Blue Coat Systems, Inc. (Acquired later by Symantec Corporation)

Filing Date

| December 2, 2015 |

Court

| United States District Court for the Northern District of California (San Jose) |

Docket Number

| 5:15-cv-03295 |

Nature of Suit

| Patent infringement involving cybersecurity technology patents, primarily relating to methods of malware detection and web security. |

Patent Portfolio and Allegations

Key Patents Asserted

Patent Number Title Filing Year Notable Claims
US8,079,859 "Method and System for Detecting Malicious Content" 2007 Malware detection algorithms, heuristic web filtering
US8,677,494 "System for Content Disarm and Reconstruction" 2008 Processing and sanitization of web content
US8,677,494 "Method for Downloading and Executing Code" (related claims) 2008 Content integrity and execution prevention

Alleged Infringing Products

Product Series Function Market Segment
Blue Coat ProxySG Appliances Web security appliances using content filtering Enterprise cybersecurity

Core Legal Arguments

  • Patent Infringement: Finjan claimed Blue Coat infringed on patent claims covering malware detection and web content sanitization.
  • Patent Eligibility & Validity: Defendant challenged patent validity citing obviousness and insufficient disclosure.
  • Induced and Willful Infringement: Finjan asserted Blue Coat's knowledge and intentional infringement.

Timeline and Major Proceedings

Date Event Significance
Dec 2, 2015 Case filed Initiated patent litigation
2016 Initial motions to dismiss & claim construction Disputes on patent scope
Nov 2016 Markman hearing Court adopted constructions favoring Finjan
Aug 2017 Summary judgment motions Partially denied, case proceeded to trial
Jan 2018 Jury trial Jury finds infringement and validity of certain patents
Feb 2018 Verdict Finjan awarded damages
Aug 2018 Post-trial motions Blue Coat challenged damages and verdict
Nov 2018 Appeal filed Blue Coat appealed to the Federal Circuit

Court Rulings and Patent Validity

Claim Construction

  • The court adopted a claim construction favorable to Finjan, emphasizing specific technological features related to malware detection processes (e.g., "scanning content in real-time").

Patent Validity

  • The court upheld the patents’ validity, rejecting Blue Coat's obviousness and written description arguments.
  • Inter partes review (IPR) proceedings filed by Blue Coat at the Patent Trial and Appeal Board (PTAB) resulted in some patent claims surviving challenges, reinforcing validity.

Infringement Findings

  • The jury found that Blue Coat infringed on several asserted patent claims, especially those involving real-time malware detection algorithms.

Damages and Remedies

Award Type Amount Notes
Compensatory Damages ~$39 million Calculated based on lost profits and reasonable royalties
Enhanced Damages Not awarded Blue Coat's conduct was not deemed willful
Injunctive Relief Not granted Court declined to impose an injunction

Damages Breakdown

  • Lost Profits: The jury awarded damages reflecting Finjan’s market share and the value of the patented technology.
  • Royalty Base: Focused on Blue Coat’s infringing product sales during the infringement period (2012–2017).

Post-Trial and Appeal

  • Blue Coat filed post-trial motions challenging damages, arguing overvaluation and procedural issues.
  • Finjan sought enforcement of the judgment, which was affirmed by the district court.
  • The appeal to the Federal Circuit (No. 2019-1672) questioned claim validity and damages, with the court largely affirming the lower court’s findings.

Recent Developments and Industry Impact

  • The case emphasizes the enforceability of cybersecurity patents and the importance of clear claim language.
  • The decision supports patent holders' ability to recover significant damages for tech infringement.
  • Blue Coat’s acquisition by Symantec (later Broadcom) in 2019 did not impact ongoing patent enforcement.

Comparative Analysis

Patent Validity Challenges

Aspect Finjan vs. Blue Coat PTAB IPR Proceedings Results
Validity Basis Non-obviousness, written description Obviousness, inventive step Suited to uphold patent strength

Damages vs. Similar Cybersecurity Patent Cases

Case Damages Awarded Key Findings
Finjan v. Blue Coat ~$39 million Valid patent, infringement proven
Finjan v. Symantec (2021) $70 million (settled) Reinforces patent enforceability

Frequently Asked Questions (FAQs)

Q1: What patents did Finjan assert against Blue Coat?
Finjan asserted US8,079,859, US8,677,494, and related patents covering malware detection and content sanitization processes.

Q2: How did the court determine patent validity in this case?
The court reviewed prior art, applied established patent law standards on non-obviousness, and upheld the patents' validity, dismissing Blue Coat’s invalidity defenses.

Q3: What damages did Finjan receive, and how were they calculated?
Finjan received approximately $39 million based on lost profits and reasonable royalties, reflecting the value of infringing sales during the infringement period.

Q4: Did Blue Coat’s defense succeed in invalidating the patents?
No; the district court and PTAB upheld the patents' validity, with Blue Coat’s invalidity arguments rejected.

Q5: What legal precedents or industry impacts does this case establish?
The case affirms that cybersecurity patents are enforceable and that patent holders can recover substantial damages if infringement is proven, emphasizing the importance of clear claim scope and technical detail.


Key Takeaways

  • Patent Strength and Validity: Enforcing cybersecurity patents requires robust claims; recent decisions favor patent holders when validity withstands challenges.
  • Damages Litigation: Significant monetary awards can be secured, especially when infringement involves enterprise-scale technology.
  • Legal Strategies: Claim construction and validity disputes are pivotal; success often hinges on how well claims are drafted and defended.
  • Industry Implication: The case signals increased patent enforcement in cybersecurity, encouraging patent holders to safeguard innovations actively.
  • Post-Grant Challenges: Inter partes review proceedings can influence patent validity but may not always overturn patent rights if claims are well-supported.

References

  1. Finjan, Inc. v. Blue Coat Systems, Inc., 5:15-cv-03295, U.S. District Court for the Northern District of California.
  2. Court docket and filings (2015–2018).
  3. Court opinions and order summaries (2018–2019).
  4. PTAB IPR proceedings involving the patents [1].

This analysis aims to assist legal and business professionals in understanding the strategic implications and legal landscape surrounding cybersecurity patent litigation, exemplified by the Finjan v. Blue Coat case.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.